IL6 and COVID-19: Sabbatinelli et al., Hermine et al., Salvarani et al., Malekzadeh et al., Dastan et al. and Rodríguez-Molinero et al. have all addressed the question of Interleukin 6 inhibitor and the outcomes on severe or critical COVID-19 patients [54,55,56,57,58,59]; amongst them two studies found clinical results that favors the intervention groups with Tocilizumab, while two are descriptive with no comparator and two showed no difference with the intervention.